• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial

byDonna LeetandAliya Ramjaun
April 6, 2019
in Chronic Disease, Oncology, Pulmonology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma

Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma

Gemcitabine with ramucirumab improved overall survival for malignant pleural mesothelioma

Malignant pleural mesothelioma is a devastating cancer, with survival rates ranging from as low as 17% to 46%. Diagnosis and/or treatment usually involves an invasive chest wall procedure, however, this carries the risk of tumor-cell seeding at the site of the procedure and subsequent development of metastases. Due to this risk, prophylactic radiotherapy is commonly delivered to the site of the chest wall procedure. However, past studies assessing the efficacy and safety of this approach have been underpowered and have produced conflicting results. In this randomized controlled trial, 375 patients with malignant pleural mesothelioma (MPM) were assigned to receive prophylactic radiotherapy or no prophylactic radiotherapy after a diagnostic or therapeutic chest wall procedure to study the impact on incidence of metastases on the ipsilateral chest wall (chest wall metastases, CWM) 6 months after randomization. There was a similar proportion of patients receiving chemotherapy in the two groups (66.7% in the prophylactic radiotherapy group, 60.3% in the no-radiotherapy group). Researchers found that there was no difference in the proportion of CWM 6 months after randomization between the two groups (3.2% in the prophylactic radiotherapy group vs. 5.3% in the no-radiotherapy group, OR 0.60, 95% CI 0.17 to 1.86, p=0.44). There was also no difference at 12 months (8.1% vs. 10.1%, respectively, OR 0.79, 95% CI 0.36 to 1.69, p=0.59). Skin toxicity was the most common radiotherapy-related adverse event, and occurred in 116 of 186 patients in the prophylactic radiotherapy group. A limitation of this study was the absence of blinding of the participants and investigators. In summary, results from this study do not support the routine use of prophylactic radiotherapy after a chest wall procedure in patients with malignant pleural mesothelioma.

Click to read the study in Journal of Clinical Oncology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: malignant pleural mesotheliomaMesotheliomaRadiation Therapy
Previous Post

In phase 3 trial, rituximab not associated with clinical improvement in patients with Myalgic encephalomyelitis/chronic fatigue syndrome

Next Post

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

RelatedReports

Dacomitinib may be effective in EGFR-associated lung cancer
Oncology

Abemaciclib linked to disease control in patients with p16ink4A-negative mesothelioma

March 27, 2022
Quick Take: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
Oncology

Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma

October 28, 2021
Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]
Chronic Disease

Gemcitabine with ramucirumab improved overall survival for malignant pleural mesothelioma

October 3, 2021
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Oncology

Younger adults with extremity soft-tissue sarcoma may be more likely to receive chemotherapy and less likely to receive radiation therapy compared to older adults

August 23, 2021
Next Post
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial

Quick Take: Outcomes of Extremely Preterm Infants With Birth Weight Less Than 400 g

#VisualAbstract: Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

#VisualAbstract: Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.